Aims : Access educational materials here Immunotherapy has already developed to a new life-prolonging therapeutic backbone in advanced non-small cell lung cancer with significantly life-prolonging checkpoint-inhibitors available not only for second line but also first line therapy in routine care. The aim of this session is to provide a most current and comprehensive update as well as a future perspective on the advanced use of established and new immunotherapeutic drugs in lung cancer. The emphasis is on the combination of immunotherapeutic drugs with present treatment modalities such as other systemic therapies or radiotherapy since these seem to bear the potential to booster immunotherapy.